Gene Logic, Inc. has entered into an agreement with Abbott to discover additional development paths for several of Abbott’s drug candidates, all of which have successfully completed Phase I trials. Under the agreement, Gene Logic is eligible to receive success-based milestone payments for each drug candidate Abbott returns to clinical development. Gene Logic will also receive royalties for each drug candidate that is marketed. Gene Logic has the option to receive an exclusive license ...